FT538

DRUG5 trials

Sponsors

Fate Therapeutics, Masonic Cancer Center, University of Minnesota

Conditions

AML, AdultARTAcute Myeloid LeukemiaCancerCd4+ Lymphocyte DeficiencyFallopian Tube CancerHIV-1-infectionInterleukin

Phase 1

FT538 in Subjects With Advanced Hematologic Malignancies

TerminatedNCT04614636

Fate TherapeuticsAcute Myeloid Leukemia, AML, Adult, Multiple Myeloma +1

Start: 2020-10-17End: 2023-08-08Updated: 2023-09-21

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

CompletedNCT04714372

Masonic Cancer Center, University of MinnesotaAcute Myeloid Leukemia, Monocytic Leukemia, Myeloid Leukemia

Start: 2021-11-03End: 2024-10-15Updated: 2024-10-24

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

TerminatedNCT05069935

Fate TherapeuticsSolid Tumor, Adult

Start: 2021-10-15End: 2023-08-11Updated: 2023-09-21

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

WithdrawnNCT05700630

Masonic Cancer Center, University of MinnesotaART, Cd4+ Lymphocyte Deficiency, HIV-1-infection +2

Start: 2024-07-15End: 2024-08-21Updated: 2024-02-26

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

TerminatedNCT05708924

Masonic Cancer Center, University of MinnesotaCancer, Fallopian Tube Cancer, Ovarian Cancer +2

Start: 2023-04-28End: 2024-08-06Updated: 2025-08-14

Related Papers

Phase I Study of FT538 + Daratumumab for Treatment of r/r AML

Blood2023-11-025 citations

365 Oxygen levels found in bone marrow (5%) provide an optimal niche for the differentiation of induced-pluripotent stem cell-derived NK cells for the treatment of AML

Regular and Young Investigator Award Abstracts2023-10-31

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Blood2022-11-157 citations

727 Interim phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2022-11-012 citations